NeuBase uses its proprietary PATrOL™ platform to design, develop, and scale precision genetic medicines to target genetic mutations at the DNA or RNA level, with ultra-high affinity and single base selectivity. Our PATrOL-enabled therapies have broad cell and tissue distribution, with the ability to penetrate cell nuclei and the deep brain.

With the ability to engage different genetic mutations, NeuBase has the potential to treat a wide range of diseases. The Company's precision genetic medicine pipeline includes a myotonic dystrophy type 1 program expected to have an IND filed by the end of 2022 and preclinical programs for Huntington's disease and cancer (KRAS G12V and G12D mutations).